| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 8.0 | — |
| Net income | -144.5 | -18.7 |
| EPS (diluted, $ a share) | $-10.19 | $-32.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: JSPR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Jasper Therapeutics, Inc.: key numbers
- Share price
- $11.77Close, Nov 16
- Market cap
- $13.1M
- Shares outstanding
- 1.11MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Jasper Therapeutics, Inc.
All →Jasper Therapeutics Financial Results
Jasper Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update following its acquisition of Kira Pharmaceuticals. The company highlighted progress in its Phase 2 renal basket study for vensobafusp alfa (KP104), including completed enrollment in the IgA nephropathy cohort and the dosing of the first patient with IC-MPGN.
“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).”
Jeet Mahal, President and Chief Executive Officer of Jasper
“We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”
Jeet Mahal, President and Chief Executive Officer of Jasper
Jasper Therapeutics Shareholder Meeting
Jasper Therapeutics convened and then adjourned its special meeting of stockholders due to the lack of a quorum. The meeting has been rescheduled to reconvene virtually on December 1, 2026, with no changes to the proposals or the record date.
Jasper Therapeutics Announces $2.76M Stock Buyback
Jasper Therapeutics completed a tender offer to repurchase 8,510,658 of its outstanding warrants at a price of $0.324 per warrant. The company will pay an aggregate of approximately $2.76 million in cash for the tendered warrants, which represent roughly 68.94% of the outstanding warrants issued in September 2025.
- Value
- $2.76M
Jasper Therapeutics Reverse Stock Split
Jasper Therapeutics announced a 1-for-30 reverse stock split of its common stock, effective November 6, 2026. The split will reduce the number of outstanding shares from approximately 33.3 million to 1.1 million to increase the per-share trading price on the Nasdaq Capital Market. The authorized number of shares remains unchanged at 490 million, resulting in an increase in authorized but unissued shares available for future use.
Jasper Therapeutics Clinical Trial Data
Jasper Therapeutics completed enrollment for the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104). The company expects to report initial interim data from this study by year-end 2026 and plans to expand the study to include patients with focal segmental glomerulosclerosis (FSGS) in early 2027.
Jasper Therapeutics Announces $4M Stock Buyback
Jasper Therapeutics has commenced a cash tender offer to repurchase all 12,345,707 of its outstanding warrants issued in September 2025 at a price of $0.324 per warrant. The company expects to pay approximately $4.0 million if all warrants are tendered, aiming to reduce potential share dilution and simplify its capital structure.
- Value
- $4M
- Term
- through Nov 6, 2026